Study of Carboplatin and Temozolomide in Advanced Melanoma
Author Information
Author(s): Strauss S J, Marples M, Napier M P, Meyer T, Boxall J, Rustin G J S
Primary Institution: Mount Vernon Cancer Centre
Hypothesis
Can the combination of carboplatin and temozolomide improve treatment outcomes for patients with advanced melanoma?
Conclusion
The combination of carboplatin and temozolomide resulted in significant myelosuppression and low response rates in patients with advanced melanoma.
Supporting Evidence
- Temozolomide has a broad spectrum of antitumour activity and good oral bioavailability.
- Patients with advanced melanoma have a poor prognosis and limited treatment options.
- The combination of temozolomide and carboplatin has not been previously tested.
Takeaway
Doctors tested a new medicine combination for patients with a serious skin cancer, but it didn't work very well and caused a lot of side effects.
Methodology
Patients with advanced melanoma were treated with escalating doses of carboplatin and temozolomide to determine the maximum tolerated dose and assess toxicity.
Limitations
The study had a small sample size and did not define a maximum tolerated dose due to significant toxicity.
Participant Demographics
{"median_age":54,"sex_distribution":{"male":16,"female":14},"brain_metastases":11,"multiple_sites_of_metastases":22}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website